Bright Minds Biosciences Inc. (DRUG)
NASDAQ: DRUG · Real-Time Price · USD
32.62
+0.13 (0.40%)
At close: May 12, 2025, 4:00 PM
32.25
-0.37 (-1.13%)
After-hours: May 12, 2025, 7:15 PM EDT
Bright Minds Biosciences Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Bright Minds Biosciences stock have an average target of 83.25, with a low estimate of 75 and a high estimate of 93. The average target predicts an increase of 155.21% from the current stock price of 32.62.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Bright Minds Biosciences stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
---|---|---|---|---|---|---|
Strong Buy | 0 | 1 | 1 | 1 | 1 | 2 |
Buy | 1 | 3 | 3 | 3 | 3 | 3 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 1 | 4 | 4 | 4 | 4 | 5 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Chardan Capital | Chardan Capital | Strong Buy Initiates $80 | Strong Buy | Initiates | $80 | +145.25% | May 7, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $85 | Strong Buy | Reiterates | $85 | +160.58% | Feb 19, 2025 |
Piper Sandler | Piper Sandler | Buy Initiates $93 | Buy | Initiates | $93 | +185.10% | Jan 23, 2025 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Jan 10, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $85 | Strong Buy | Initiates | $85 | +160.58% | Jan 10, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock
Revenue Forecast
No data available
Revenue Growth
No data available
EPS Forecast
No data available
EPS Growth
No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.